Do analysts prefer KALA or KVAC?

KALA BIO presently has a consensus target price of $1,158.33, indicating a potential upside of 217,550.01%. Given KALA BIO's higher possible upside, equities analysts plainly believe KALA BIO is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, KALA or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is KALA or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% Keen Vision Acquisition N/A N/A N/A

Is IMA or KALA more profitable?

ImageneBio's return on equity of -38.99% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% KALA BIO N/A -222.35% -70.23%

Does the media favor IMA or KALA?

In the previous week, ImageneBio and ImageneBio both had 5 articles in the media. ImageneBio's average media sentiment score of 1.27 beat KALA BIO's score of 0.47 indicating that ImageneBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XLO or KALA?

KALA BIO has a consensus price target of $1,158.33, indicating a potential upside of 217,550.01%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XLO or KALA more profitable?

KALA BIO has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Xilio Therapeutics -34.06% -71.99% -20.43% KALA BIO N/A -222.35% -70.23%

Does the media favor XLO or KALA?

In the previous week, KALA BIO had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for KALA BIO and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.82 beat KALA BIO's score of 0.47 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer KALA or APLM?

KALA BIO presently has a consensus target price of $1,158.33, suggesting a potential upside of 217,550.01%. Given KALA BIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe KALA BIO is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, KALA or APLM?

Apollomics has higher revenue and earnings than KALA BIO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A Apollomics $8.50M 6.97 -$10.94M N/A N/A

Is KALA or APLM more profitable?

Apollomics' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% Apollomics N/A N/A N/A

Which has preferable earnings & valuation, KALA or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is KALA or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% MiNK Therapeutics N/A N/A -92.37%

KALA BIO (KALA) Competitors

$0.53 -0.14 (-20.89%)

As of 04:00 PM Eastern

Compare

KALA vs. KVAC, IMA, XLO, APLM, and INKT

Should you buy KALA BIO stock or one of its competitors? KALA BIO's main competitors and comparable companies include Keen Vision Acquisition (KVAC), ImageneBio (IMA), Xilio Therapeutics (XLO), Apollomics (APLM), and MiNK Therapeutics (INKT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does KALA BIO compare to Keen Vision Acquisition?

KALA BIO (NASDAQ:KALA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

KALA BIO has a beta of -2.28, suggesting that its stock price is 328% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

KALA BIO presently has a consensus target price of $1,158.33, indicating a potential upside of 217,550.01%. Given KALA BIO's higher possible upside, equities analysts plainly believe KALA BIO is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
Keen Vision Acquisition	N/A	N/A	N/A

In the previous week, KALA BIO had 5 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 5 mentions for KALA BIO and 0 mentions for Keen Vision Acquisition. KALA BIO's average media sentiment score of 0.47 beat Keen Vision Acquisition's score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Neutral
Keen Vision Acquisition	Neutral

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Keen Vision Acquisition beats KALA BIO on 5 of the 9 factors compared between the two stocks.

How does KALA BIO compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 477.69%. KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 217,550.01%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

KALA BIO has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	71.22	-$45.35M	-$4.58	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

In the previous week, ImageneBio and ImageneBio both had 5 articles in the media. ImageneBio's average media sentiment score of 1.27 beat KALA BIO's score of 0.47 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImageneBio's return on equity of -38.99% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
KALA BIO	N/A	-222.35%	-70.23%

ImageneBio has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, indicating that its share price is 328% less volatile than the broader market.

Summary

ImageneBio beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

KALA BIO has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.33	-$35.04M	-$1.64	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

In the previous week, KALA BIO had 4 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for KALA BIO and 1 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 1.82 beat KALA BIO's score of 0.47 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

KALA BIO has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
KALA BIO	N/A	-222.35%	-70.23%

Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.28, meaning that its share price is 328% less volatile than the broader market.

KALA BIO has a consensus price target of $1,158.33, indicating a potential upside of 217,550.01%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Xilio Therapeutics beats KALA BIO on 8 of the 15 factors compared between the two stocks.

How does KALA BIO compare to Apollomics?

KALA BIO (NASDAQ:KALA) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, KALA BIO had 5 more articles in the media than Apollomics. MarketBeat recorded 5 mentions for KALA BIO and 0 mentions for Apollomics. Apollomics' average media sentiment score of 1.89 beat KALA BIO's score of 0.47 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Neutral
Apollomics	Very Positive

KALA BIO presently has a consensus target price of $1,158.33, suggesting a potential upside of 217,550.01%. Given KALA BIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe KALA BIO is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

KALA BIO has a beta of -2.28, suggesting that its share price is 328% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Apollomics' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
Apollomics	N/A	N/A	N/A

Apollomics has higher revenue and earnings than KALA BIO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
Apollomics	$8.50M	6.97	-$10.94M	N/A	N/A

Summary

KALA BIO and Apollomics tied by winning 6 of the 12 factors compared between the two stocks.

How does KALA BIO compare to MiNK Therapeutics?

KALA BIO (NASDAQ:KALA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, KALA BIO had 5 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for KALA BIO and 0 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.87 beat KALA BIO's score of 0.47 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
KALA BIO	Neutral
MiNK Therapeutics	Very Positive

KALA BIO has a beta of -2.28, indicating that its share price is 328% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MiNK Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
MiNK Therapeutics	N/A	N/A	-92.37%

KALA BIO currently has a consensus price target of $1,158.33, indicating a potential upside of 217,550.01%. MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 219.63%. Given KALA BIO's higher probable upside, equities research analysts clearly believe KALA BIO is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MiNK Therapeutics beats KALA BIO on 6 of the 11 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.01M	$3.94B	$7.15B	$12.83B
Dividend Yield	N/A	3.61%	2.53%	11.79%
P/E Ratio	-0.02	6.94	211.64	21.64
Price / Sales	N/A	1,331.29	618.40	91.53
Price / Cash	N/A	106.63	77.20	52.85
Price / Book	1.13	16.59	12.92	6.03
Net Income	-$26.98M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-35.18%	-2.35%	-0.84%	-2.42%
1 Month Performance	-29.59%	11.57%	7.15%	2.94%
1 Year Performance	-99.91%	54.76%	24.74%	13.69%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	2.7596 of 5 stars	$0.53 -20.9%	$1,158.33 +217,550.0%	-99.9%	$13.01M	N/A	N/A	30	News Coverage Gap Down High Trading Volume
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
IMA ImageneBio	3.1839 of 5 stars	$5.43 -2.2%	$29.00 +434.1%	-61.9%	$63M	$800K	N/A	70	Positive News
XLO Xilio Therapeutics	0.239 of 5 stars	$9.05 -0.3%	N/A	-8.7%	$59.75M	$43.77M	N/A	70	Positive News
APLM Apollomics	2.5323 of 5 stars	$26.20 -1.1%	N/A	+589.3%	$58.19M	$8.50M	N/A	45	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors

KALA vs. KVAC, IMA, XLO, APLM, and INKT

How does KALA BIO compare to Keen Vision Acquisition?

Summary

How does KALA BIO compare to ImageneBio?

Summary

How does KALA BIO compare to Xilio Therapeutics?

Summary

How does KALA BIO compare to Apollomics?

Summary

How does KALA BIO compare to MiNK Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KALA BIO (KALA) Competitors

KALA vs. KVAC, IMA, XLO, APLM, and INKT

How does KALA BIO compare to Keen Vision Acquisition?

Which has more volatility & risk, KALA or KVAC?

Do analysts prefer KALA or KVAC?

Is KALA or KVAC more profitable?

Does the media refer more to KALA or KVAC?

Do institutionals and insiders believe in KALA or KVAC?

Which has higher earnings & valuation, KALA or KVAC?

Summary

How does KALA BIO compare to ImageneBio?

Do institutionals and insiders hold more shares of IMA or KALA?

Do analysts recommend IMA or KALA?

Which has higher earnings & valuation, IMA or KALA?

Does the media favor IMA or KALA?

Is IMA or KALA more profitable?

Which has more risk and volatility, IMA or KALA?

Summary

How does KALA BIO compare to Xilio Therapeutics?

Which has better valuation and earnings, XLO or KALA?

Does the media favor XLO or KALA?

Is XLO or KALA more profitable?

Which has more volatility & risk, XLO or KALA?

Do analysts rate XLO or KALA?

Do institutionals & insiders have more ownership in XLO or KALA?

Summary

How does KALA BIO compare to Apollomics?

Do insiders & institutionals believe in KALA or APLM?

Does the media refer more to KALA or APLM?

Do analysts prefer KALA or APLM?

Which has more risk & volatility, KALA or APLM?

Is KALA or APLM more profitable?

Which has better earnings & valuation, KALA or APLM?

Summary

How does KALA BIO compare to MiNK Therapeutics?

Does the media favor KALA or INKT?

Which has more risk & volatility, KALA or INKT?

Which has preferable earnings & valuation, KALA or INKT?

Do insiders & institutionals have more ownership in KALA or INKT?

Is KALA or INKT more profitable?

Do analysts rate KALA or INKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools